"targeted AC-225-radiopharmaceutical for metastatic uveal melanoma"period of performance: 9/18/2017 - 9/17/2019

Ended Definitive Contract Awarded Last action

Contract number
HHSN261201700035C
Awardee
Awarding agency
Obligated
$1,999,987

Award facts

Opportunity
  • N44CO7701794 Solicitation number
Contract value 100% obligated
$1,999,987.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Everettville, WV 26505, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00004 $0
Other Administrative Action P00003 $0
Other Administrative Action P00002 $0
Other Administrative Action 1 $0
Original award $1,999,987

About this award

The U.S. National Cancer Institute awarded a $1,999,987.00 Firm Fixed Price definitive contract to Modulation Therapeutics, Inc., a woman-owned small business, to develop a "TARGETED AC-225-RADIOPHARMACEUTICAL FOR METASTATIC UVEAL MELANOMA". The contract has a period of performance from September 18, 2017 to September 17, 2019, with a total small business set-aside. The place of performance is Morgantown, West Virginia.

Quick answers

Who was awarded contract HHSN261201700035C?

HHSN261201700035C was awarded to Modulation Therapeutics, Inc. by National Cancer Institute (National Institutes of Health) on September 18, 2017.

How much is contract HHSN261201700035C worth?

The government has obligated $1,999,987 on HHSN261201700035C.

Was contract HHSN261201700035C competed?

The extent of competition for HHSN261201700035C was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award